(Q37322123)

19 August 2017

1 reference

title

Cholestasis and metabolic bone disease - a clinical review (English)

1 reference

19 August 2017

1 reference

metabolic bone disease

1 reference

Rudolf W Gasser

1

1 reference

19 August 2017

publication date

1 January 2008

1 reference

Wiener Medizinische Wochenschrift

19 August 2017

published in

1 reference

19 August 2017

volume

158

1 reference

19 August 2017

issue

19-20

1 reference

19 August 2017

page(s)

553-557

1 reference

https://scigraph.springernature.com/pub.10.1007/s10354-008-0594-z

19 August 2017

exact match

0 references

cites work

Zoledronic acid prevents bone loss after liver transplantation: a randomized, double-blind, placebo-controlled trial

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10354-008-0594-Z

Treatment of osteoporosis in patients with chronic liver disease and in liver transplant recipients

21 January 2018

1 reference

12 December 2020

Osteoporosis in primary biliary cirrhosis: effects of 25-hydroxyvitamin D3 treatment.

1 reference

12 December 2020

Experimental cholestatic liver disease through bile-duct ligation in rats results in skeletal fragility and impaired osteoblastogenesis

1 reference

12 December 2020

Evaluation and management of osteoporosis in liver disease

1 reference

12 December 2020

Osteoporosis in liver diseases and after liver transplantation

1 reference

12 December 2020

Extrahepatic manifestations of cholestatic liver diseases: pathogenesis and therapy

1 reference

12 December 2020

Role of hyperbilirubinemia in the impairment of osteoblast proliferation associated with cholestatic jaundice

1 reference

12 December 2020

Transdermal hormone replacement therapy improves vertebral bone density in primary biliary cirrhosis: results of a 1-year controlled trial.

1 reference

12 December 2020

Guidelines on the management of osteoporosis associated with chronic liver disease

1 reference

12 December 2020

An open, randomized, controlled study of transdermal hormone replacement therapy on the rate of bone loss in primary biliary cirrhosis

1 reference

12 December 2020

Bone disease in cholestatic liver disease

1 reference

12 December 2020

Bone metabolism in advanced cholestatic liver disease: analysis by bone histomorphometry

1 reference

12 December 2020

Oestradiol and testosterone blood levels in patients with viral cirrhosis and hepatocellular carcinoma.

1 reference

12 December 2020

Randomized pilot trial of vitamin K2 for bone loss in patients with primary biliary cirrhosis.

1 reference

12 December 2020

Alendronate in combination with calcium and vitamin D prevents bone loss after orthotopic liver transplantation: a prospective single-center study

1 reference

12 December 2020

The RANKL/OPG system and bone mineral density in patients with chronic liver disease.

1 reference

12 December 2020

Plasma vitamin K1 level is decreased in primary biliary cirrhosis

1 reference

12 December 2020

Impairment of bone mass development in children with chronic cholestatic liver disease

1 reference

12 December 2020

Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group

1 reference

12 December 2020

Osteoporosis in Primary Biliary Cirrhosis: A Randomized Trial of the Efficacy and Feasibility of Estrogen/Progestin

1 reference

12 December 2020

Gene polymorphisms as predictors of decreased bone mineral density and osteoporosis in primary biliary cirrhosis

1 reference

12 December 2020

Bone disease in primary biliary cirrhosis: independent indicators and rate of progression.

1 reference

12 December 2020

Glucocorticosteroids for primary biliary cirrhosis

1 reference

12 December 2020

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

1 reference

12 December 2020

High serum osteoprotegerin and low RANKL in primary biliary cirrhosis

1 reference

12 December 2020

Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis

1 reference

12 December 2020

Hepatic osteodystrophy.

1 reference

12 December 2020

Bone mineral metabolism and histomorphometry in rats with cholestatic liver disease

1 reference

12 December 2020

Serum osteoprotegerin and RANKL levels in chronic alcoholic liver disease.

1 reference

12 December 2020

Raloxifene improves bone mass in osteopenic women with primary biliary cirrhosis: results of a pilot study

1 reference

12 December 2020

Alendronate improves bone mineral density in primary biliary cirrhosis: a randomized placebo-controlled trial

1 reference

12 December 2020

Serum osteoprotegerin and its ligand in cirrhotic patients referred for orthotopic liver transplantation: relationship with metabolic bone disease

1 reference

12 December 2020

Glucocorticosteroids for primary sclerosing cholangitis

1 reference

12 December 2020

Bone mineral density before and after OLT: long-term follow-up and predictive factors.

1 reference

12 December 2020

Bone disease in primary biliary cirrhosis: histologic features and response to 25-hydroxyvitamin D

1 reference

12 December 2020

Inappropriately low levels of gonadotrophins in amenorrhoeic women with alcoholic and non-alcoholic cirrhosis

1 reference

12 December 2020

Hyperbilirubinemia is not a major contributing factor to altered bone mineral density in patients with chronic liver disease.

1 reference

12 December 2020

Treatment of bone disorders in liver disease

1 reference

12 December 2020

10.1007/S10354-008-0594-Z

Identifiers

DOI

1 reference

19 August 2017

1 reference